


## COMPANION DIAGNOSTICS

The effective use of anticancer therapeutics targeting defined cancer-driving molecular abnormalities often requires tests called companion diagnostics. Companion diagnostics:

are stringently tested for accuracy, sensitivity, and fidelity;



are regulated by the U.S. Food and Drug Administration;



accurately match patients with a specific therapy;



allow patients to receive a treatment to which they are most likely to respond; and



allow patients identified as very unlikely to respond to forgo treatment with the therapeutic and thus be spared adverse side effects.



Adapted from (1)

*American Association for Cancer Research  
(AACR) Cancer Progress Report 2019*